A multicentre multinational randomised parallel-group placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin FlexPro in adults with growth hormone deficiency for 35 weeks with a 53-week extension period (PRIME)

A multicentre  multinational  randomised  parallel-group  placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin  FlexPro  in adults with growth hormone deficiency for 35 weeks  with a 53-week extension period (PRIME)

Brief description of study

The trial will compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily dosing of Norditropin® in adult subjects with growth hormone deficiency.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Dwarfism, Pituitary Dwarfism, growth hormone deficiency, pituitary gland
  • Age: Between 1 Years - 99 Years
  • Gender: All
Updated on 29 Sep 2022. Study ID: 821145

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center